TIAA CREF Investment Management LLC Has $1.72 Million Holdings in Genomic Health, Inc. (GHDX)

TIAA CREF Investment Management LLC decreased its holdings in Genomic Health, Inc. (NASDAQ:GHDX) by 26.0% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 52,684 shares of the medical research company’s stock after selling 18,549 shares during the quarter. TIAA CREF Investment Management LLC owned about 0.15% of Genomic Health worth $1,715,000 as of its most recent filing with the SEC.

Other large investors have also added to or reduced their stakes in the company. Eagle Asset Management Inc. increased its position in shares of Genomic Health by 18.4% in the second quarter. Eagle Asset Management Inc. now owns 379,473 shares of the medical research company’s stock valued at $12,351,000 after buying an additional 58,920 shares in the last quarter. American International Group Inc. increased its position in Genomic Health by 7.1% during the 1st quarter. American International Group Inc. now owns 11,505 shares of the medical research company’s stock worth $362,000 after purchasing an additional 765 shares in the last quarter. Schwab Charles Investment Management Inc. increased its position in Genomic Health by 8.6% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 482,675 shares of the medical research company’s stock worth $15,200,000 after purchasing an additional 38,199 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Genomic Health by 38.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 294,048 shares of the medical research company’s stock worth $9,259,000 after purchasing an additional 81,425 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in Genomic Health by 8.8% during the 1st quarter. Vanguard Group Inc. now owns 1,564,170 shares of the medical research company’s stock worth $49,256,000 after purchasing an additional 126,807 shares in the last quarter. Hedge funds and other institutional investors own 89.13% of the company’s stock.

A number of analysts recently commented on GHDX shares. Zacks Investment Research upgraded Genomic Health from a “sell” rating to a “hold” rating in a research report on Friday, October 13th. Cowen and Company reissued a “hold” rating and issued a $34.00 price target on shares of Genomic Health in a research note on Friday, September 1st. Jefferies Group LLC reissued a “hold” rating and issued a $33.00 price target on shares of Genomic Health in a research note on Thursday, September 14th. BidaskClub raised Genomic Health from a “sell” rating to a “hold” rating in a research note on Saturday, August 26th. Finally, Piper Jaffray Companies reaffirmed a “hold” rating and issued a $31.00 price objective on shares of Genomic Health in a research note on Thursday, August 3rd. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and one has issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $32.00.

ILLEGAL ACTIVITY NOTICE: “TIAA CREF Investment Management LLC Has $1.72 Million Holdings in Genomic Health, Inc. (GHDX)” was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at https://ledgergazette.com/2017/11/13/tiaa-cref-investment-management-llc-has-1-72-million-stake-in-genomic-health-inc-ghdx.html.

In related news, insider James J. Vaughn sold 1,379 shares of the business’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $32.51, for a total transaction of $44,831.29. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO G Bradley Cole sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $31.86, for a total value of $159,300.00. The disclosure for this sale can be found here. Insiders sold a total of 21,379 shares of company stock valued at $676,131 over the last quarter. Company insiders own 46.20% of the company’s stock.

Shares of Genomic Health, Inc. (GHDX) opened at $29.17 on Monday. Genomic Health, Inc. has a twelve month low of $26.37 and a twelve month high of $34.02.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply